ReviewFrontiers in immunology2021
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Integrating ConvNeXt tiny and radiomics in a nomogram to differentiate true progression from pseudoprogression in glioma.Neuroradiology · 2026Article
- The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.Physics in medicine and biology · 2026Review
- Early Detection and Inhibition of Post-Surgical Cancer Recurrence by Synthetic Extracellular Vesicles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow-up strategies.Bioengineering & translational medicine · 2026Review
- Integrative machine learning reveals hidden and emerging co-regulatory gene networks for multi-phase glioblastoma outcome prediction.European journal of cancer (Oxford, England : 1990) · 2026Article
- Review
- AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.Frontiers in immunology · 2026Review
- Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.Nature communications · 2025Article
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
- Review
- Liquid Biopsy as a Diagnostic and Monitoring Tool in Glioblastoma.Medicina (Kaunas, Lithuania) · 2025Review
- Treatment of Non-Hodgkin Lymphoma Involving Head and Neck Sites with a 1.5 T MR-Linac: Preliminary Results from a Prospective Observational Study.Hematology reports · 2025Article
- Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.Brain sciences · 2025Article
- Enhancement of the nontumor component in newly diagnosed glioblastoma as a more accurate predictor of local recurrence location: a multicenter study.Quantitative imaging in medicine and surgery · 2025Article
- Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges.Frontiers in oncology · 2025Review
- Distinguishing glioblastoma progression from treatment-related changes using DTI directionality growth analysis.Neuroradiology · 2024Article
- Review
- Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.Journal for immunotherapy of cancer · 2024Article
- Recurrence Patterns after Radiotherapy for Glioblastoma with [(11)C]methionine Positron Emission Tomography-Guided Irradiation for Target Volume Optimization.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.